Qureator is proud to announce its selection as a shortlisted finalist for the renowned Lush Prize in the Science category. This prestigious initiative awards £50,000 to projects that drive the transition toward practical, regulator-accepted non-animal testing methods.
View the full shortlist: https://lushprize.org/2026-prize/2026-prize-shortlist/
Qureator Appoints Paul Park as Consulting Chief Business Officer
We are thrilled to welcome Paul Park to Qureator as our new Consulting CBO. Paul brings over 20 years of executive experience from Amgen, Ionis, and Circle Pharma, with a proven track record in strategy, M&A, and high-impact partnerships.
Qureator is proud to announce a new partnership with the Physicians Committee for Responsible Medicine (PCRM) to host an exclusive in-person workshop during the Society of Toxicology (SOT) 2026 Annual Meeting in San Diego. This collaboration reflects our shared commitment to advancing human-relevant, non-animal approaches in next-generation toxicology and risk assessment.
Qureator extends its sincere appreciation to The BIO for its in-depth reporting on our landmark FDA IND approval achieved without animal PoC data. The coverage underscores a transformative moment for the global drug-development landscape and highlights the pivotal collaboration between Qureator and SillaJen.
Following a landmark FDA IND approval that validated its animal-free vTIME platform, Qureator is launching new anti–PD-1/L1 and PD-1/VEGF bispecific campaigns with a special, limited-time offer for partners.
Qureator announced the world’s first FDA Investigational New Drug (IND) approval for an oncology therapy, SillaJen’s BAL0891, based solely on efficacy data from our human vascularized organ-on-a-chip (vTIME) platform, successfully replacing traditional animal studies.
Qureator is proud to unveil the future of drug discovery at BIO 2025.
Qureator is proud to announce its participation at ARVO 2025, unveiling its pioneering iPSC-derived 3D outer Blood-Retinal Barrier (oBRB) model. Using Curiochips™ technology, the model faithfully replicates key features of both…